Xenon Pharmaceuticals Inc. - Common Stock (XENE)

CUSIP: 98420N105

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class
Equity / Common Stock
Shares outstanding
76,851,274
Total 13F shares
83,131,091
Share change
+6,419,626
Total reported value
$2,602,180,922
Put/Call ratio
93%
Price per share
$31.30
Number of holders
206
Value change
+$191,395,540
Number of buys
118
Number of sells
95

Quarterly Holders Quick Answers

What is CUSIP 98420N105?
CUSIP 98420N105 identifies XENE - Xenon Pharmaceuticals Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2025

As of 30 Jun 2025, Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by 206 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 83,131,091 shares. The largest 10 holders included FMR LLC, Avoro Capital Advisors LLC, BlackRock, Inc., Driehaus Capital Management LLC, BRAIDWELL LP, JANUS HENDERSON GROUP PLC, Capital International Investors, Commodore Capital LP, Polar Capital Holdings Plc, and WELLINGTON MANAGEMENT GROUP LLP. This page lists 206 institutional shareholders reporting positions in this security for the Q2 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.